{"filings":[{"id":93874,"accession_number":"0001585364-26-000044","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Perrigo Q1 net sales $969M (-7.2%), adj EPS $0.43 (-28%); reaffirms FY 2026 outlook","event_type":"earnings","confidence":"high","bullets":["All In net sales $969M, down 7.2% YoY; reported diluted EPS $(2.81) due to $330.8M goodwill impairment.","Core adjusted EPS $0.40, down 20% YoY; Core organic net sales -11.0% reflecting lower seasonal cough/cold and retailer destocking.","After quarter end, completed Dermacosmetics sale for upfront cash of €306M; proceeds to support debt reduction.","Self Care segment net sales down 11.5%, operating income down 39.3% due to lower volumes and prior-year manufacturing headwinds.","Full-year 2026 outlook reaffirmed; expects second-half improvement from lapping headwinds and OEP."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":969200000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93873,"accession_number":"0001193125-26-206401","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Perrigo shareholders approve 2026 LTIP, re-elect all director nominees at AGM","event_type":"other","confidence":"high","bullets":["2026 Long-Term Incentive Plan approved (101.5M for); replaces 2019 Plan. Authorized pool: 7.265M new shares plus forfeitures.","All nine director nominees elected; strongest support for Kevin Egan (106.6M votes), lowest for Albert Manzone (92.1M).","Advisory 'say-on-pay' vote (105.4M for) and auditor ratification (113.5M for) passed.","Board authority to issue shares and opt-out of pre-emption rights under Irish law renewed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93872,"accession_number":"0001585364-26-000040","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Perrigo completes sale of Dermacosmetics business for €305.6M upfront, plus contingent €27M","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash €305.6M (incl. €5.6M working capital); up to €27M contingent on net sales milestones over three years.","Brands sold: ACO, Biodermal, Emolium, Iwostin; business generated ~€120M net sales (~5% of adj. op income) in 2025.","Net proceeds will be used primarily for debt reduction, enhancing financial flexibility and strengthening balance sheet.","Divestiture is part of Perrigo's Three-S plan to Stabilize, Streamline, and Strengthen the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93871,"accession_number":"0001585364-26-000035","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Perrigo revises segment reporting; FY2025 includes $1.36B impairment charge","event_type":"other_material","confidence":"high","bullets":["Self Care segment net sales $2,533.5M in FY2025, down from $2,554.3M in FY2024.","Infant Formula segment net sales $359.0M in FY2025, down from $397.0M in FY2024.","Adjusted operating income for segments totaled $682.6M in FY2025, consolidated adjusted operating income $622.3M.","Q4 2025 goodwill impairment of $1.3B plus $33.6M equity method impairment contributed to reported operating loss of $1,122.2M.","Segment change effective Q1 2026; recast historical data provided for comparability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105840,"accession_number":"0001585364-26-000028","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Perrigo amends credit facility: $1.0B revolver (2031) & $972M term loan B (2029)","event_type":"debt","confidence":"high","bullets":["Entered Amended and Restated Credit Agreement on March 20, 2026, with JPMorgan and others.","Revolving credit facility increased to $1.0B, maturing March 20, 2031; term loan B unchanged at $972.4M maturing April 20, 2029.","Proceeds from revolver drawdown used to prepay Term A Loans in full, plus accrued interest and fees.","Credit spread adjustment on revolving loans eliminated; maturity of revolver tied to 91 days before term loan or 4.900% notes if outstanding.","Covenants include max secured net leverage ratio and minimum cash interest coverage; secured by assets and equity interests of loan parties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105839,"accession_number":"0001585364-26-000006","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Perrigo Q4 adj. EPS $0.77 vs $0.93 YoY; records $1.3B goodwill impairment; FY2026 outlook $2.00-$2.30","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $1.11B (-2.5% YoY); reported EPS ($10.20) from $1.3B goodwill impairment.","FY2025 adj. EPS $2.75 (+7% YoY); organic net sales -2.4%.","FY2026 All-in adj. EPS guidance $2.00-$2.30; CORE adj. EPS $2.25-$2.55 (excl. infant formula and divestitures).","New operational enhancement program targets $80M-$100M in annualized pre-tax savings.","Potential additional goodwill impairment of up to $350M in Q1 2026 from reporting unit reallocation."],"consensus_eps_estimate":null,"consensus_eps_actual":-10.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":4253100000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122109,"accession_number":"0001585364-25-000153","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Perrigo Q3 adj EPS $0.80 flat YoY; cuts FY25 guide; starts infant formula review","event_type":"earnings","confidence":"high","bullets":["Q3 net sales $1.04B (-4.1% YoY); adj EPS $0.80 vs $0.81; reported EPS $0.09 vs -$0.13.","FY25 outlook lowered: net sales growth -2.5% to -3.0%, adj EPS $2.70-$2.80 (5%-9% YoY growth).","Initiates strategic review of infant formula business; continues oral care review; Dermacosmetics sale on track for Q1 2026.","OTC store brand gained dollar, unit, and volume share in 5 of 7 categories despite soft market.","YTD adj operating income up 9.8% to $455M; benefits from Project Energize and Supply Chain Reinvention."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":3143500000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138827,"accession_number":"0001585364-25-000120","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Perrigo Q2 2025 Adj EPS $0.57 beats $0.53; net sales $1.06B down 0.9% YoY","event_type":"earnings","confidence":"high","bullets":["Reported EPS $0.00 vs $(0.77); Adj EPS $0.57 up 7.5% YoY on lower interest expense from reduced debt.","Net sales $1,056M down 0.9% YoY; organic net sales flat (-0.1%); CSCI organic +2.7%, CSCA organic -1.9%.","Reported operating income $45M vs $(27M) loss; Adj operating income $135M down 2.9% due to infant formula scrap and lower plant absorption.","Reaffirms FY2025 adj EPS target $2.90-$3.10; topline expected towards lower end of previous ranges.","Announced agreement to sell Dermacosmetics business, expected close Q1 2026; proceeds to strengthen balance sheet."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":2100200000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138826,"accession_number":"0001193125-25-158493","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Perrigo to sell Dermacosmetics business to KKR for up to €327M","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash €300M, plus up to €27M milestone payments over three years.","Divestiture includes brands ACO, Biodermal, Emolium, Iwostin; 2024 net sales ~€125M.","Expected to close Q1 2026; net proceeds to strengthen balance sheet.","Advances Perrigo's 'Three-S' plan to streamline portfolio and focus on high-growth brands.","Business generated ~5% of Perrigo's 2024 adjusted operating income."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138825,"accession_number":"0001193125-25-154126","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Perrigo restructures leadership; Triona Schmelter departs, Roberto Khoury named EVP & CCO","event_type":"leadership","confidence":"high","bullets":["Triona Schmelter, EVP & President Consumer Self-Care Americas, departs June 30 due to position elimination; remains advisory until Oct 31.","Roberto Khoury appointed EVP & Chief Commercial Officer effective July 1, from prior role leading Consumer Self-Care International.","Organizational alignment scales global category-led, market activation model; roles of EVP Pres CSCI and CSCA discontinued.","2025 adjusted EPS guidance unchanged; restructuring part of multi-year Stabilize, Streamline and Strengthen plan.","Perrigo notes growth model already delivering results in CSCI and increasingly in CSCA; aims to unlock brand and store brand portfolio value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156297,"accession_number":"0001193125-25-134980","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Perrigo EVP Global Ops Ron Janish to retire; Matt Winterman appointed as successor","event_type":"leadership","confidence":"high","bullets":["Ron Janish steps down June 23, 2025; advisory role through Sep 30, 2025.","Janish receives 2.5x salary plus target bonus severance, equity vesting per agreement.","Matt Winterman named EVP Product Supply, Operations Strategy & Transformation Officer, effective June 23.","Winterman previously SVP Global Supply Chain at AstraZeneca, overseeing $54B supply chain.","Winterman also held supply chain leadership roles at Roche and GSK."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}